Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects of non childbearing potential and/or healthy male subjects, between the ages of 18 and 55 years.~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg.~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).~* History of cerebrovascular accident, transient ischemic attack (TIA), or traumatic brain injury.~* History of seizures or history or physical examination findings (eg localizing signs on neurologic examination) suggestive of structural central nervous system (CNS) abnormalities which may place patient at increased risk of seizures.~* History of orthostatic blood pressure changes or clinically significant orthostatic symptoms.~* Self reported history or risk factors for QT prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia, congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness, family history of sudden death, and family history of long QT syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PF-04447943 low dose (Type: EXPERIMENTAL): 25 mg of PF-04447943
- PF-04447943 high dose (Type: EXPERIMENTAL): 100 mg of PF-04447943
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for PF-04447943
- Moxifloxacin (Type: ACTIVE_COMPARATOR): 400 mg of moxifloxacin

Based on this trial design, predict the completion outcome and termination type (if applicable).